Pulmonary fibrosis is a condition that causes lung scarring and stiffness. It develops when the alveoli, tiny air sacs that transfer oxygen to the blood, become damaged and inflamed. Body tries to heal the damage with scars, but these scars collapse the alveoli and make the lungs less elastic. Changes in the lungs can also increase the blood pressure in the pulmonary artery. This condition, called pulmonary hypertension, makes the heart work harder and it may fail. It can result from many different lung diseases including sarcoidosis, drug reactions, autoimmune diseases, environmental allergies such as Farmer's lung, and exposure to toxic dusts and gases.
Statistical analysis on pulmonary fibrosis in Argentina resulted as First, study of the evolvement of the host response following the injection of a cell clone (L-1D) that produced on average 20% or less SPARC than control L-CMV cells. Eight hours after injection, we observed a similar inflammatory response in both L-1D and L-CMV injection sites, which was probably the result of host response to the xenogeneic transplant (data not shown). However, 24 hours was enough to observe clear histologic differences between samples.
Indeed, mice injected with L-CMV cells showed tumour nodules with a conspicuous PMN infiltrate. These tumours continued growing for over 12 days showing an increased extracellular matrix layer and only a scant PMN infiltrate. Conversely, injection of L-1D cells at 24 to 72 hours resulted in an increased inflammatory infiltrate compared with L-CMV cells.